Article Text

Download PDFPDF
Stroke and thromboembolism prevention in atrial fibrillation
  1. Sina Jame,
  2. Geoffrey Barnes
  1. Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to Dr Geoffrey Barnes, University of Michigan, Ann Arbor, MI 48109-1382, USA; gbarnes{at}


Prevention of stroke and systemic thromboembolism remains the cornerstone for management of atrial fibrillation (AF) and flutter. Multiple risk assessment models for stroke and systemic thromboembolism are currently available. The score, with its known limitations, remains as the recommended risk stratification tool in most major guidelines. Once at-risk patients are identified, vitamin K antagonists (VKAs) and, more recently, direct oral anticoagulants (DOACs) are the primary medical therapy for stroke prevention. In those with contraindication for long-term anticoagulation, left atrial appendage occluding devices are developing as a possible alternative therapy. Some controversy exists regarding anticoagulation management for cardioversion of acute AF (<48 hours); however, systemic anticoagulation precardioversion and postcardioversion is recommended for those with longer duration of AF. Anticoagulation management peri-AF ablation is also evolving. Uninterrupted VKA and DOAC therapy has been shown to reduce perioperative thromboembolic risk with no significant escalation in major bleeding. Currently, under investigation is a minimally interrupted approach to anticoagulation with DOACs periablation. Questions remain, especially regarding the delivery of anticoagulation care and integration of wearable rhythm monitors in AF management.

  • Atrial Fibrillation
  • Anticoagulation
  • Stroke
  • Arrhythmia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Both authors contributed significantly to the conception, initial drafting and significant revisions of the manuscript.

  • Funding National Heart, Lung, and Blood Institute (K01HL135392 to GDB).

  • Competing interests GB: grant funding from Pfizer/Bristol-Myers Squib, Blue Cross Blue Shield of Michigan, National Heart, Lung, and Blood Institute. Consulting fees from Pfizer/Bristol-Myers Squib, Janssen, Portola and AMAG Pharmaceuticals.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.